You are viewing the site in preview mode

Skip to main content


Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient

Fig. 1

Expression of Fractalkine/CX3CL1 in human colon cancer tissues and cell lines. a Immunostaining score of Fractalkine/CX3CL1 in 171 patients with colorectal cancer; numbers on top of bars define exact number of patients with a given score; b Immunostaining of Fractalkine/CX3CL1 in human normal colonic mucosa (top) and in a representative human colon cancer tissue (bottom); c Immunofluorescence by confocal microscopy of Fractalkine/CX3CL1 protein expression in NCI-H630 cells and d in RKO cells upon transduction of the Fractalkine cDNA (CX3CL1-cherry) or mock-transduced (mock-cherry); e Quantification by ELISA of Fractalkine/CX3CL1 levels in the lysate of NCI-H630 tumors grown in NSG mice, normal skin tissue was used as reference control; f ELISA of Fractalkine/CX3CL1 levels in tumor lysates obtained from RKO tumors (RKO-MOCK and RKO-CX3CL1) grown in NSG mice

Back to article page